Brown Vance R 4

What Happened
Vance R. Brown, EVP, General Counsel and Corporate Secretary of Boston Scientific (BSX), exercised/converted derivative awards and received new awards on Feb 12, 2026. The filing shows conversion/exercise of 1,442 derivative shares (priced at $0.00) and grant/award entries of 7,420 and 17,510 shares (derivative/RSU-type awards). To satisfy tax withholding, 488 shares were surrendered/disposed at $74.12 each, yielding about $36,171. These actions are primarily awards and an exercise/conversion rather than an open-market sale or purchase.

Key Details

• Transaction date: February 12, 2026; Form 4 filed Feb 17, 2026 (appears one business day late for a Feb 12 transaction).
• Exercises/conversions: 1,442 shares @ $0.00 (reported as derivative exercise/conversion, code M).
• Tax withholding: 488 shares disposed @ $74.12 = $36,171 (code F).
• Grants/awards: 7,420 and 17,510 shares reported as awards/grants @ $0.00 (code A).
• Shares owned after transaction: Not specified in the provided filing details.
• Transaction codes: M = option/derivative exercise or conversion; F = payment of tax liability via share surrender; A = grant/award.

Context

• The exercise/conversion at $0.00 plus immediate surrender of 488 shares to cover taxes indicates a cashless-like tax withholding rather than an open-market sale for investment purposes.
• Footnotes clarify these are restricted stock units (RSUs) or option awards: RSUs represent the company’s commitment to issue one share per unit; some RSUs/options vest in installments — certain RSUs issue in four equal annual installments beginning Feb 12, 2025 or Feb 12, 2027, and the option grant vests in four equal annual installments beginning Feb 12, 2027 (see filing footnotes F1–F4).
• These entries are routine award/vesting and tax-withholding actions; they are informational and do not, by themselves, indicate the insider's market view.